Skip to main content
Premium Trial:

Request an Annual Quote

Dell Leads $22 Million VC Investment in Edico Genome

CHICAGO (GenomeWeb) – Sequencing informatics technology developer Edico Genome has closed a $22 million Series B funding round, led by new investor Dell Technologies Capital. All previous venture investors, including Qualcomm Ventures, Axon Ventures, and NuVasive CEO Greg Lucier, participated in this round, San Diego-based Edico said today.

Edico is looking to use the new money to continue development and marketing of Dragen, the company's field-programmable gate array bioinformatics processor.

"Dell’s backing will help enable the Dragen platform to radically change healthcare by unlocking data to reveal new insight into diseases, speed critical diagnoses, and guide precision medicine," Edico CEO Pieter van Rooyen said in a statement.

Dell Technologies Capital is the investment arm of tech giant Dell Technologies. In January, Dell subsidiary Dell EMC reached an agreement with Edico to integrate the Dragen processor into a 1U Dell 4130 server for genome analysis, as well as into Dell EMC's Isilon scale-out networked attached storage for genomic data storage.